Cargando…

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study

PURPOSE: The primary objective of this study was to assess long-term safety with sublingual asenapine 2.5 or 5 mg twice daily (BID) in patients with schizophrenia. PATIENTS AND METHODS: Actively treated patients on asenapine 2.5 mg BID, asenapine 5 mg BID, or olanzapine 15 mg once daily (QD) who com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durgam, Suresh, Landbloom, Ronald P, Mackle, Mary, Wu, Xiao, Mathews, Maju, Nasrallah, Henry A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546824/ https://www.ncbi.nlm.nih.gov/pubmed/28814871 http://dx.doi.org/10.2147/NDT.S130211

Ejemplares similares

Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial
por: Findling, Robert L., et al.
Publicado: (2016)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Gommoll, Carl, et al.
Publicado: (2015)

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
por: Gommoll, Carl, et al.
Publicado: (2015)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome, Leslie, et al.
Publicado: (2017)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
por: Cazorla, Pilar, et al.
Publicado: (2012)

Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
por: Kinoshita, Toshihiko, et al.
Publicado: (2016)

Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
por: Bishara, Delia, et al.
Publicado: (2009)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Asenapine-induced double incontinence: A rare case report
por: Singh, Gurvinder Pal, et al.
Publicado: (2014)

Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis
por: Cazorla, Pilar, et al.
Publicado: (2013)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
por: Stepanova, Ekaterina, et al.
Publicado: (2017)

Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone
por: Khan, Arif, et al.
Publicado: (2016)

Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report
por: Ochi, Shinichiro, et al.
Publicado: (2019)

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia
por: Ogyu, Kamiyu, et al.
Publicado: (2020)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
por: Gopal, Srihari, et al.
Publicado: (2017)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
por: Savitz, Adam J., et al.
Publicado: (2019)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
por: Blackwood, Clifton, et al.
Publicado: (2020)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

A Review of Asenapine in the Treatment of Bipolar Disorder
por: Vieta, Eduard, et al.
Publicado: (2017)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia
por: Maitra, Arpita, et al.
Publicado: (2020)

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials
por: Szegedi, Armin, et al.
Publicado: (2011)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication
por: Kinoshita, Toshihiko, et al.
Publicado: (2023)

Asenapine effects in animal models of psychosis and cognitive function
por: Marston, Hugh M., et al.
Publicado: (2009)

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
por: Lachaine, Jean, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rs4h4uai2ailfvlv4bv35qfb7h